PL3995135T3 - Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym - Google Patents

Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym

Info

Publication number
PL3995135T3
PL3995135T3 PL20206800.3T PL20206800T PL3995135T3 PL 3995135 T3 PL3995135 T3 PL 3995135T3 PL 20206800 T PL20206800 T PL 20206800T PL 3995135 T3 PL3995135 T3 PL 3995135T3
Authority
PL
Poland
Prior art keywords
tapentadol
dosage form
acid salt
tartaric acid
release dosage
Prior art date
Application number
PL20206800.3T
Other languages
English (en)
Inventor
Ulrike Bertram
Ulrich Reinhold
Christian Grosse
Carmen HARTMANN
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73343829&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3995135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL3995135T3 publication Critical patent/PL3995135T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20206800.3T 2020-11-10 2020-11-10 Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym PL3995135T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20206800.3A EP3995135B1 (de) 2020-11-10 2020-11-10 Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure

Publications (1)

Publication Number Publication Date
PL3995135T3 true PL3995135T3 (pl) 2022-10-03

Family

ID=73343829

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20206800.3T PL3995135T3 (pl) 2020-11-10 2020-11-10 Postać dawkowania zapewniająca przedłużone uwalnianie soli tapentadolu z kwasem l-(+)-winowym

Country Status (10)

Country Link
EP (1) EP3995135B1 (pl)
AU (1) AU2021201353B1 (pl)
DK (1) DK3995135T3 (pl)
ES (1) ES2927147T3 (pl)
HR (1) HRP20221136T1 (pl)
HU (1) HUE059465T2 (pl)
LT (1) LT3995135T (pl)
PL (1) PL3995135T3 (pl)
PT (1) PT3995135T (pl)
RS (1) RS63521B1 (pl)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
BRPI0718320A2 (pt) 2006-10-27 2013-11-26 Janssen Pharmaceutica Nv Composições farmacêuticas secas granuladas e métodos para produzir as mesmas.
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
KR102146233B1 (ko) 2010-07-23 2020-08-21 그뤼넨탈 게엠베하 ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정
EP3027214A1 (en) 2013-08-02 2016-06-08 ratiopharm GmbH Composition comprising tapentadol in a dissolved form
AU2015237721B2 (en) * 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US10182992B2 (en) * 2014-04-07 2019-01-22 Patheon Softgels Inc. Abuse-deterrent controlled release formulations
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
EP3377049B1 (en) 2015-11-17 2021-01-06 MSN Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
ES2963929T3 (es) * 2017-05-29 2024-04-03 Gruenenthal Gmbh Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol
CN111346077B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种他喷他多透皮给药的药物组合物及其制备方法和应用
EP3875079A1 (en) * 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt

Also Published As

Publication number Publication date
HRP20221136T1 (hr) 2022-11-25
EP3995135A1 (de) 2022-05-11
DK3995135T3 (da) 2022-08-22
PT3995135T (pt) 2022-09-08
AU2021201353B1 (en) 2022-04-21
HUE059465T2 (hu) 2022-11-28
EP3995135B1 (de) 2022-07-13
RS63521B1 (sr) 2022-09-30
LT3995135T (lt) 2022-08-25
ES2927147T3 (es) 2022-11-02

Similar Documents

Publication Publication Date Title
IL254854B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
IN2015DN01673A (pl)
SG10202012352XA (en) Triesters of cyclohexanetripropionic acid
IL305851A (en) Preparation of 2-chloro-4-fluoro-5-nitrobenzoic acid
IL199608A (en) Aqueous composition containing ammonium salt of abscisic acid - s - (+) and a method for its preparation
DK3377049T3 (en) Crystalline forms of tapentadol salts and process for preparation thereof
PT3995135T (pt) Forma de dosagem que proporciona libertação prolongada de um sal de tapentadol com ácido l-(+)-tartárico
PL3875077T3 (pl) Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu
GB202006715D0 (en) Methods of making nucleioc acid nanostructures
MX343986B (es) Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
GB202017267D0 (en) Process of preparing active pharmaceutical ingredient salts
HK1250655A1 (zh) 用於口服給藥的他噴他多的水性藥物製劑
IN2013MU03424A (pl)
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas